Takeda’s zasocitinib shows superior efficacy in Phase 3 psoriasis trials

Zasocitinib achieved statistical superiority over deucravacitinib across the primary and all key secondary efficacy endpoints

Pfizer’s LITFULO shows significant repigmentation in Phase 3 vitiligo trials

LITFULO has dual selectivity for JAK3 and the TEC family kinases

Teva’s Tourette drug shows rapid & sustained tic reduction in new data

The data add to the evidence behind ecopipam as the drug awaits a decision from the US Food and Drug Administration under Priority Review

AstraZeneca, Daiichi Sankyo & Summit team up to test cancer drug combination

The companies plan to begin with a Phase III study in patients with previously untreated triple-negative breast cancer

Sun Pharma’s LEQSELVI shows sustained hair regrowth through two years

The data tracked patients for up to two years and found that the safety profile of LEQSELVI remained generally consistent with earlier clinical experience

Roche’s giredestrant shows significant progression-free survival benefit in advanced breast cancer trial

Overall survival data remain immature, although the study showed a positive trend in both the overall population and the ESR1-mutated subgroup

Lilly’s oral GLP-1 linked to lower predicted risk of diabetes & heart disease

The findings showed the largest modeled reduction in diabetes risk among patients taking the 17.2 mg dose

Zealand Pharma’s survodutide delivers up to 13.1% weight loss in Phase III obesity trial

The company said Boehringer Ingelheim’s SYNCHRONIZE-2 trial met both of its co-primary endpoints,

AbbVie’s zumilokibart shows positive phase 2 results in atopic dermatitis

The study’s primary endpoint was the proportion of patients achieving at least a 75% improvement from baseline in the Eczema Area

Lilly’s Foundayo shows greater weight loss than oral semaglutide in indirect analysis

The latest analysis drew on data from Lilly’s ACHIEVE-3 trial and the PIONEER PLUS study of oral semaglutide

Astellas launches Phase 3 trial of KRAS G12D-targeted drug in advanced lung cancer

The move marks the second Phase 3 study of setidegrasib launched by Astellas within six months

AstraZeneca’s Trixeo approved in the EU for the maintenance treatment of asthma

In the trials, Trixeo demonstrated statistically significant improvements in lung function compared with combined ICS/LABA comparators

Roche’s Sefaxersen cuts kidney protein in phase III trial

Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage

Roche’s Lunsumio combination meets key Phase III endpoint in follicular lymphoma

The results could support Roche’s push to move Lunsumio into earlier lines of treatment

Syntis Bio reports weight-loss signals for oral obesity drug in Phase 1/1b Trial

SYNT-101 was designed to produce a specific multi-hormone signature, one that mimics the metabolic response of bariatric surgery but via a once-daily oral tablet

Tagrisso delivers eight-year survival benefit in early-stage EGFR-mutated lung cancer

AbbVie’s Atogepant delivers positive Phase 3 results in menstrual migraine

The drug also achieved statistically significant and clinically meaningful improvements across all eight ranked secondary endpoints

AstraZeneca’s Etcamah falls short of key Phase III endpoint in breast cancer trial

The SERENA-4 trial did not meet its primary endpoint of progression-free survival (PFS) in patients with estrogen receptor (ER)-positive

AstraZeneca’s Tozorakimab cuts COPD exacerbations by up to 34% in broad Phase III population

The reduction was particularly notable across eosinophil thresholds

Labcorp acquires MLM Medical Labs to strengthen global clinical trial services

The acquisition brings MLM’s laboratory network and scientific service capabilities into Labcorp’s global infrastructure, expanding the company’s wholly owned laboratory footprint